Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

OBJECTIVE: We aimed to evaluate the cost-effectiveness of voretigene neparvovec (VN) compared with standard of care (SoC) for patients with inherited retinal disease (IRD) caused by a biallelic RPE65-mutation. VN is a live, non-replicating adeno-associated virus serotype 2 (AAV2). SoC is best suppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhadhuri, Arjun, Dröschel, Daniel, Guldimann, Mike, Jetschgo, Claudia, Banhazi, Judit, Schwenkglenks, Matthias, Sutherland, C. Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241179/
https://www.ncbi.nlm.nih.gov/pubmed/35765055
http://dx.doi.org/10.1186/s12913-022-08211-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241179/
https://www.ncbi.nlm.nih.gov/pubmed/35765055
http://dx.doi.org/10.1186/s12913-022-08211-y

Ejemplares similares